Newscast – Page 94 – media

Another immunometabolism deal? Johns Hopkins spinout Dracen lands $36M investment from Deerfield

The company, founded just a year ago, is developing novel glutamine antagonists that work as inhibitors of cancer metabolism, choking out tumors and their normal metabolic function.
- Source: Endpts
- 674
- April 3, 2018
cancer inhibitor Market Views metabolism
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, announced that its exclusive North American licensee for bremelanotide, AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. If approved, bremelanotide would become the first and only as desired pharmacologic option in the U.S. indicated for the treatment of HSDD in premenopausal women.
- Source: drugs
- 637
- April 3, 2018
bremelanotide FDA New Approvals
Takeda moots Shire move but big questions remain

Takeda is considering making a bold move for Shire, after announcing, as per UK regulations, that it may make an approach for the company.
- Source: takeda
- 720
- April 3, 2018
Company Insights Shire Takeda
Record Q1 brings in $1.6B for digital health investments, disease diagnosis segment dominates

Investment in digital health rose to its highest level for the first quarter of the year at $1.6 billion compared with $909 million for the same time last year, according to a new report by Rock Health. That figure reflected investment across 77 digital health deals, dominated by the category of disease diagnosis in terms of total investment and monitoring of disease category in terms of deal volume.
- Source: MedCityNews
- 670
- April 3, 2018
Company Insights digital health investment
Tiny ‘hearing’ device is 100,000 times thinner than your eardrum

The super small vibrating sensor can detect signals at the highest reported dynamic range of frequencies, up to ~110dB, at radio frequencies (RF) up to over 120MHz.
- Source: Engadget
- 1,266
- April 3, 2018
medical device Researches wearables
Parkinson’s gene initiates disease outside of the brain

Until very recently, Parkinson's had been thought a disease that starts in the brain, destroying motion centers and resulting in the tremors and loss of movement. New research published this week in the journal Brain, shows the most common Parkinson's gene mutation may change how immune cells react to generic infections like colds, which in turn trigger the inflammatory reaction in the brain that causes Parkinson's. The research offers a new understanding of Parkinson's disease.
- Source: sciencedaily
- 699
- April 2, 2018
immune cells Parkinson’s disease Researches
Calorie restriction trial in humans suggests benefits for age-related disease

One of the first studies to explore the effects of calorie restriction on humans showed that cutting caloric intake by 15% for 2 years slowed aging and metabolism and protected against age-related disease. The study, which will appear March 22 in the journal Cell Metabolism, found that calorie restriction decreased systemic oxidative stress, which has been tied to age-related neurological conditions such as Alzheimer's and Parkinson's diseases, as well as cancer, diabetes, and others.
- Source: sciencedaily
- 660
- April 2, 2018
aging calorie restriction metabolism Researches
Nine digital health mergers and acquisitions from the first quarter of 2018

The first quarter of 2018 was light on mergers and acquisitions compared to previous quarters, but those that did crop up were significant, including major companies like Fitbit, Allscripts, Roche, and Johnson & Johnson.
- Source: MobiHealthNews
- 560
- April 2, 2018
digital health Market Views merger-and-acquisition
Siren launches smart sock for diabetes patients, announces $3.4M in funding

The company, which was founded in 2015, also announced that it has raised $3.4 million in seed funding, from DCM, Khosla Ventures, and Founders Fund.
- Source: Mobile Health News
- 752
- April 2, 2018
Company Insights diabetes digital health mHealth
Third Rock debuts immunometabolism startup Rheos with $60M launch round

Global pharmaceutical company Mylan N.V. (MYL) today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR), indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.
- Source: pharmacompass
- 720
- March 30, 2018
financing immune Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.